J Uberti
Overview
Explore the profile of J Uberti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
225
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Al-Kadhimi Z, Gul Z, Abidi M, Lum L, Deol A, Chen W, et al.
Bone Marrow Transplant
. 2017 Jun;
52(9):1304-1310.
PMID: 28581472
Chronic GvHD (cGvHD) is the leading cause of late non-relapse mortality (NRM) and morbidity after allogeneic hematopoietic stem cell transplant (AHSCT). We analyzed the late effects of a phase II...
2.
Gul Z, Van Meter E, Abidi M, Ditah I, Abdul-Hussein M, Deol A, et al.
Bone Marrow Transplant
. 2015 Jan;
50(3):432-7.
PMID: 25599169
Multiple reports have shown that low absolute lymphocyte count at day 30 (ALC30) after allogeneic hematopoietic SCT (AHSCT) is associated with higher risk of disease relapse and worse OS. However,...
3.
Shaughnessy P, Uberti J, Devine S, Maziarz R, Vose J, Micallef I, et al.
Bone Marrow Transplant
. 2012 Nov;
48(6):777-81.
PMID: 23178544
Before US regulatory approval, an expanded access program provided plerixafor to patients with non-Hodgkin's lymphoma (NHL), Hodgkin's lymphoma (HD) or multiple myeloma (MM) who had not previously failed mobilization and...
4.
Micallef I, Jacobsen E, Shaughnessy P, Gandhi P, Calandra G, van Rhee F, et al.
Bone Marrow Transplant
. 2012 Jul;
48(2):303-4.
PMID: 22773123
No abstract available.
5.
Douglas K, Parker A, Hayden P, Rahemtulla A, DAddio A, Lemoli R, et al.
Bone Marrow Transplant
. 2011 Mar;
47(1):18-23.
PMID: 21358693
We describe 20 patients with myeloma and 1 with primary amyloidosis from 15 centres, all with advanced renal failure, most of whom had PBSC mobilised using plerixafor following previous failed...
6.
Jacobson P, Ng J, Ratanatharathorn V, Uberti J, Brundage R
Bone Marrow Transplant
. 2002 Jan;
28(8):753-8.
PMID: 11781626
Tacrolimus is an immunosuppressant commonly used in the prevention of graft-versus-host disease (GVHD) following allogeneic HCT. Unfortunately, the use of tacrolimus is associated with variable immunosuppression and toxicity. The purpose...
7.
Ayash L, Clarke M, Adams P, Ferrara J, Ratanatharathorn V, Reynolds C, et al.
Hum Gene Ther
. 2001 Dec;
12(16):2023-5.
PMID: 11727734
High-dose chemotherapy (HDCT) and autologous bone marrow transplantation (BMT) is frequently used to treat patients with metastatic cancer including breast cancer and neuroblastoma. However, the bone marrow of such patients...
8.
Reynolds C, Ratanatharathorn V, Adams P, Braun T, Silver S, Ayash L, et al.
Bone Marrow Transplant
. 2001 Jul;
27(8):801-7.
PMID: 11477436
This study compares the probability of disease progression, progression-free survival, and overall survival between patients undergoing an allogeneic or autologous transplant for multiple myeloma using an identical preparative regimen. Patients...
9.
Lark R, McNeil S, VanderHyde K, Noorani Z, Uberti J, Chenoweth C
Clin Infect Dis
. 2001 Jul;
33(3):338-43.
PMID: 11438899
The incidence of anaerobic bloodstream infections (BSI) in patients who underwent bone marrow transplantation (BMT) recently increased at our institution. A retrospective case-control study of patients undergoing BMT from January...
10.
Ayash L, Clarke M, SILVER S, Braun T, Uberti J, Ratanatharathorn V, et al.
Bone Marrow Transplant
. 2001 Jul;
27(9):939-47.
PMID: 11436104
Testicular cancer patients refractory or in relapse after primary chemotherapy have < or =25% 5-year progression-free survival with salvage. To improve prognosis, patients entered a phase I/II tandem dose-escalation trial...